Generic placeholder image

Current Vascular Pharmacology


ISSN (Print): 1570-1611
ISSN (Online): 1875-6212


Nonalcoholic Fatty Liver Disease and Helicobacter pylori Infection: Is it Time to Address this Potential Relationship?

Author(s): Stergios A. Polyzos* and Jannis Kountouras

Volume 21, Issue 2, 2023

Published on: 20 February, 2023

Page: [78 - 80] Pages: 3

DOI: 10.2174/1570161121666230209161617

Makri ES, Makri E, Polyzos SA. Combination therapies for nonalcoholic fatty liver disease. J Pers Med 2022; 12(7): 1166.
[] [PMID: 35887662]
Polyzos SA, Kechagias S, Tsochatzis EA. Review article: non‐alcoholic fatty liver disease and cardiovascular diseases: Associations and treatment considerations. Aliment Pharmacol Ther 2021; 54(8): 1013-25.
[] [PMID: 34416040]
Franceschi F, Gasbarrini A, Polyzos SA, Kountouras J. Extragastric diseases and Helicobacter pylori. Helicobacter 2015; 20 (Suppl. 1): 40-6.
[] [PMID: 26372824]
Choi JM, Park HE, Han YM, et al. Non-alcoholic/metabolic-associated fatty liver disease and Helicobacter pylori additively increase the risk of arterial stiffness. Front Med 2022; 9: 844954.
[] [PMID: 35280895]
Polyzos SA, Kountouras J, Papatheodorou A, et al. Helicobacter pylori infection in patients with nonalcoholic fatty liver disease. Metabolism 2013; 62(1): 121-6.
[] [PMID: 22841522]
Polyzos SA, Kountouras J. Helicobacter pylori infection and nonalcoholic fatty liver disease: Time for large clinical trials evaluating eradication therapy. Helicobacter 2019; 24(3): e12588.
[] [PMID: 30950170]
Polyzos SA, Kountouras J, Mantzoros CS. Helicobacter pylori infection and nonalcoholic fatty liver disease: Are the four meta-analyses favoring an intriguing association pointing to the right direction? Metabolism 2019; 96: iii-v.
[] [PMID: 31121179]
Polyzos SA, Nikolopoulos P, Stogianni A, Romiopoulos I, Katsinelos P, Kountouras J. Effect of Helicobacter pylori eradication on hepatic steatosis, nafld fibrosis score and hsensi in patients with nonalcoholic steatohepatitis: A MR imaging-based pilot open-label study. Arq Gastroenterol 2014; 51(3): 261-8.
[] [PMID: 25296089]
Jamali R, Mofid A, Vahedi H, Farzaneh R, Dowlatshahi S. The effect of Helicobacter pylori eradication on liver fat content in subjects with non-alcoholic Fatty liver disease: a randomized open-label clinical trial. Hepat Mon 2013; 13(12): e14679.
[] [PMID: 24358044]
Maharshi V, Gupta P, Kumar VL, et al. Effect of Helicobacter pylori-eradication therapy on hepatic steatosis in patients with non-alcoholic fatty liver disease: A randomized–controlled pilot study. Gastroenterol Rep 2020; 8(2): 104-10.
[] [PMID: 32499918]
Abdel-Razik A, Mousa N, Shabana W, et al. Helicobacter pylori and non‐alcoholic fatty liver disease: A new enigma? Helicobacter 2018; 23(6): e12537.
[] [PMID: 30246507]
Salehi H, Minakari M, Yaghoutkar A, Tabesh E, Salehi M, Mirbagher L. The effect of Helicobacter pylori eradication on liver enzymes in patients referring with unexplained hypertransaminasemia. Adv Biomed Res 2014; 3(1): 131.
[] [PMID: 24949302]
Chen CX, Mao YS, Foster P, Zhu ZW, Du J, Guo CY. Possible association between Helicobacter pylori infection and nonalcoholic fatty liver disease. Appl Physiol Nutr Metab 2017; 42(3): 295-301.
[] [PMID: 28177748]
Polyzos SA, Kountouras J, Zavos C, Deretzi G. The association between Helicobacter pylori infection and insulin resistance: A systematic review. Helicobacter 2011; 16(2): 79-88.
[] [PMID: 21435084]

© 2024 Bentham Science Publishers | Privacy Policy